Cara Therapeutics (CARA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Cara Therapeutics (CARA) as a strong on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Cara Therapeutics

(

CARA

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Cara Therapeutics as such a stock due to the following factors:

  • CARA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $4.2 million.
  • CARA has traded 50,292 shares today.
  • CARA is trading at 3.94 times the normal volume for the stock at this time of day.
  • CARA is trading at a new high 10.02% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CARA with the Ticky from Trade-Ideas. See the FREE profile for CARA NOW at Trade-Ideas

More details on CARA:

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Currently there are 5 analysts that rate Cara Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Cara Therapeutics has been 320,800 shares per day over the past 30 days. Cara has a market cap of $418.6 million and is part of the health care sector and drugs industry. Shares are up 58.3% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Cara Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.

Highlights from the ratings report include:

  • CARA THERAPEUTICS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, CARA THERAPEUTICS INC reported poor results of -$0.78 versus -$0.10 in the prior year. For the next year, the market is expecting a contraction of 35.9% in earnings (-$1.06 versus -$0.78).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 55.9% when compared to the same quarter one year ago, falling from -$3.65 million to -$5.68 million.
  • Net operating cash flow has declined marginally to -$4.25 million or 0.35% when compared to the same quarter last year. Despite a decrease in cash flow CARA THERAPEUTICS INC is still fairing well by exceeding its industry average cash flow growth rate of -46.79%.
  • CARA, with its decline in revenue, underperformed when compared the industry average of 11.3%. Since the same quarter one year prior, revenues slightly dropped by 8.9%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • Compared to other companies in the Biotechnology industry and the overall market, CARA THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...